Mandate

Vinge advises NOTE in connection with the company’s underwritten rights issue

March 11, 2010

Vinge is advising NOTE AB (publ) in connection with the new issue of shares for approximately SEK 87 million with pre-emption rights for NOTE’s shareholders. The rights issue is conditional upon approval by the members at an extraordinary general meeting to be held on 7 April 2010. The new issue is fully underwritten by a subscription agreement and guarantee commitment by NOTE’s major shareholders.

NOTE is listed on NASDAQ OMX Stockholm. Note’s business concept is to provide electronics manufacturing and logistics services.

Vinge’s team consisted of Ola Sandersson, Dain Nevonen and Christian Granqvist. Bo Adrianzon is the responsible partner.

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025